Analysis of Botulinum Neurotoxin Serotype A Metalloprotease Inhibitors: Analogs of a Chemotype for Therapeutic Development in the Context of a Three-Zone Pharmacophore
- PMID: 21103387
- PMCID: PMC2983112
- DOI: 10.2147/OAB.S7251
Analysis of Botulinum Neurotoxin Serotype A Metalloprotease Inhibitors: Analogs of a Chemotype for Therapeutic Development in the Context of a Three-Zone Pharmacophore
Abstract
Botulinum neurotoxins (BoNTs), and in particular serotype A, are the most poisonous of known biological substances, and are responsible for the flaccid paralysis of the disease state botulism. Because of the extreme toxicity of these enzymes, BoNTs are considered highest priority biothreat agents. To counter BoNT serotype A (BoNT/A) poisoning, the discovery and development of small molecule, drug-like inhibitors as post-intoxication therapeutic agents has been/is being pursued. Specifically, we are focusing on inhibitors of the BoNT/A light chain (LC) (ie, a metalloprotease) subunit, since such compounds can enter neurons and provide post-intoxication protection of the enzyme target substrate. To aid/facilitate this drug development effort, a pharmacophore for inhibition of the BoNT/A LC subunit was previously developed, and is continually being refined via the incorporation of novel and diverse inhibitor chemotypes. Here, we describe several analogs of a promising therapeutic chemotype in the context of the pharmacophore for BoNT/A LC inhibition. Specifically, we describe: 1) the pharmacophoric 'fits' of the analogs and how these 'fits' rationalize the in vitro inhibitory potencies of the analogs and 2) pharmacophore refinement via the inclusion of new components from the most potent of the presented analogs.
Conflict of interest statement
The authors report no conflicts of interest in this work.
Figures




Similar articles
-
Natural Compounds and Their Analogues as Potent Antidotes against the Most Poisonous Bacterial Toxin.Appl Environ Microbiol. 2018 Nov 30;84(24):e01280-18. doi: 10.1128/AEM.01280-18. Print 2018 Dec 15. Appl Environ Microbiol. 2018. PMID: 30389764 Free PMC article.
-
Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors.Bioorg Med Chem. 2011 Dec 15;19(24):7338-48. doi: 10.1016/j.bmc.2011.10.062. Epub 2011 Oct 26. Bioorg Med Chem. 2011. PMID: 22082667 Free PMC article.
-
Pharmacophore Refinement Guides the Rational Design of Nanomolar-Range Inhibitors of the Botulinum Neurotoxin Serotype A Metalloprotease.ACS Med Chem Lett. 2010 Oct 14;1(7):301-305. doi: 10.1021/ml100056v. ACS Med Chem Lett. 2010. PMID: 21116458 Free PMC article.
-
8-Hydroxyquinoline and hydroxamic acid inhibitors of botulinum neurotoxin BoNT/A.Curr Top Med Chem. 2014;14(18):2094-102. doi: 10.2174/1568026614666141022095114. Curr Top Med Chem. 2014. PMID: 25335884 Review.
-
The use of small molecules to investigate molecular mechanisms and therapeutic targets for treatment of botulinum neurotoxin A intoxication.ACS Chem Biol. 2006 Jul 21;1(6):359-69. doi: 10.1021/cb600179d. ACS Chem Biol. 2006. PMID: 17163773 Review.
Cited by
-
The synthesis of 2,5-bis(4-amidinophenyl)thiophene derivatives providing submicromolar-range inhibition of the botulinum neurotoxin serotype A metalloprotease.Eur J Med Chem. 2012 Jul;53:374-9. doi: 10.1016/j.ejmech.2012.03.043. Epub 2012 Mar 30. Eur J Med Chem. 2012. PMID: 22516424 Free PMC article.
-
Natural Compounds and Their Analogues as Potent Antidotes against the Most Poisonous Bacterial Toxin.Appl Environ Microbiol. 2018 Nov 30;84(24):e01280-18. doi: 10.1128/AEM.01280-18. Print 2018 Dec 15. Appl Environ Microbiol. 2018. PMID: 30389764 Free PMC article.
-
Small-molecule quinolinol inhibitor identified provides protection against BoNT/A in mice.PLoS One. 2012;7(10):e47110. doi: 10.1371/journal.pone.0047110. Epub 2012 Oct 11. PLoS One. 2012. Retraction in: PLoS One. 2013 Sep 05;8(9). doi: 10.1371/annotation/049f74d0-919f-483c-a488-4740ec0a5f4d. PMID: 23071727 Free PMC article. Retracted.
-
Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors.Bioorg Med Chem. 2011 Dec 15;19(24):7338-48. doi: 10.1016/j.bmc.2011.10.062. Epub 2011 Oct 26. Bioorg Med Chem. 2011. PMID: 22082667 Free PMC article.
References
-
- Willis B, Eubanks LM, Dickerson TJ, Janda KD. The strange case of the botulinum neurotoxin: using chemistry and biology to modulate the most deadly poison. Angew Chem Int Ed Engl. 2008;47(44):8360–8379. - PubMed
-
- Bhidayasiri R, Truong DD. Expanding use of botulinum toxin. J Neurol Sci. 2005;235(1–2):1–9. - PubMed
-
- Cheng CM, Chen JS, Patel RP. Unlabeled uses of botulinum toxins: a review, part 1. Am J Health Syst Pharm. 2006;63(2):145–152. - PubMed
-
- Cheng CM, Chen JS, Patel RP. Unlabeled uses of botulinum toxins: a review, part 2. Am J Health Syst Pharm. 2006;63(3):225–232. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources